gms | German Medical Science

130. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

30.04. - 03.05.2013, München

Evaluation of IRI Prevention in Liver Transplantation with Infliximab (anti-TNF): preliminary results in a study group of patients with MELD>30

Meeting Abstract

Suche in Medline nach

  • Paolo Girotti - uniklinikum Tübingen, allgemein,visceral und transplantation chirurgie, Tübingen
  • Alfred Königsrainer - Universitätsklinik Tübingen, llgemeine-, Viszeral- und Transplantationschirurgie, Tübingen
  • Silvio Nadalin - Uniklinikum Tübingen, Allgemein-, Visceral- und Transplantationschirurgie, Tübingen

Deutsche Gesellschaft für Chirurgie. 130. Kongress der Deutschen Gesellschaft für Chirurgie. München, 30.04.-03.05.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13dgch728

doi: 10.3205/13dgch728, urn:nbn:de:0183-13dgch7286

Veröffentlicht: 26. April 2013

© 2013 Girotti et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Introduction: Ischemia-Reperfusion Injury (IRI) represents a complex series of intracellular and extracellular events that results in molecular, cellular and tissue damage. It´s induced by the transient deprivation of blood flow and oxygen, with lack of aerobic methabolism, and the return of blood flow during reperfusion with concomitant induction of innate and adaptive immunity, due to a release of oxygen-free radicals (OFR), cytokines/chemokines, and up-regulation of adhesion molecules, with consequent cellular and organ dysfunction. Focused on solid organ transplantation field, IRI is the main physiophatological event, resulting from an activation of TNF, that induce always an initial damage and that potentially could improvement the damage and the development of clinical syndromes, (DGF, PNF)

Material and methods: Trial Design: Prosective, monocentric, placebo-controlled study to evaluate of Infliximab (one shot) in the early post operative period (24hours) after liver graft reperfusion.

Primary Endpoints: evaluation of significant statistical reduction of IRI due to the following laboratory values at 6-12-24 h after reperfusion: ALAT, Bilirubin, CHE, CD4

Secondary Endpoints: statistical reduction of the occurrence of PDF, PNF, Acute rejection, biliary complication

Results: Study group: 7 patients (infliximab after 30 min)
Control group: 7 patients
Table 1 [Tab. 1].

Conclusion: Infliximab injection after 30 min after liver graft reperfusion showed good results in term of fast reduction of injury labor liver values. It seems to influence a reduction of iperacute complications (PNF and AR) but not the risk of development of PDF and late biliary complications. Preliminary results and the number of patients in this study should be increased.